From today's announcement: Dr John Wilkinson remains as Chief Scientific Officer but will have a focus on supporting the Veyonda clinical program. This is a required key focus with the program facing a significant increase in clinical activity in 2020 including the prospect of Veyonda entering a registration study in 2020.
24-week data for the 1200 mg expansion cohort in DARRT-1 is due in November, just before the AGM. If the data are good, as they should be given the excellent responses after 12 weeks, it looks like Noxopharm intends to jump from Phase I direct into a registration trial.
Add to My Watchlist
What is My Watchlist?
